Winchester, MA, United States of America

Karina Macek

This inventor holds 1 USPTO granted patent. Top assignee: Ariad Pharmaceuticals, Inc.. Active years: 2003.


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Karina Macek

Introduction

Karina Macek is a notable inventor based in Winchester, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the area of signal transduction inhibitors. His work has implications for both therapeutic and veterinary applications.

Latest Patents

Karina Macek holds 1 patent for his invention titled "Signal transduction inhibitors, compositions containing them." This invention focuses on compounds that inhibit intracellular signal transduction, especially those mediated by molecular interactions involving phosphotyrosine-containing proteins. The patent also encompasses pharmaceutical compositions containing these compounds, along with methods for their prophylactic and therapeutic administration.

Career Highlights

Karina Macek is associated with Ariad Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in his field. His expertise in signal transduction has positioned him as a valuable asset to the company.

Collaborations

Throughout his career, Karina has collaborated with notable colleagues, including Michael G Yang and Chester A Metcalf, III. These collaborations have further enriched his research and contributed to the success of his inventions.

Conclusion

Karina Macek's innovative work in the realm of signal transduction inhibitors showcases his dedication to advancing pharmaceutical science. His contributions are vital for developing new therapeutic methods and improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…